Positively-charged liposomes for targeting tumor vasculature

Nanotechnology for Cancer Therapy

Volumn , Issue , 2006, Pages 613-627

  Campbell, Robert B ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85132514952     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (94)

1. Jain, R. K., Vascular and interstitial barriers to delivery of therapeutic agents in tumors, Cancer Metastasis Rev., 9, 253-266, 1990.
2. Simionescu, M., Simionescu, N., and Palade, G. E., Morphometric data on the endothelium of blood capillaries, J. Cell Biol., 60, 128-152, 1974.
3. Simionescu, M., Simionescu, N., and Palade, G. E., Structural basis of permeability in sequential segments of the microvasculature. I. Bipolar microvascular fields in the diaphragm, Microvasc. Res., 15, 1-16, 1978.
4. Simionescu, M., Simionescu, N., Santoro, F., and Palade, G. E., Differentiated microdomains of the luminal plasmalemma of murine muscle capillaries: Segmental variations in young and old animals, J. Cell Biol., 100, 1396-1407, 1985.
5. Ghinea, N. and Simionescu, N., Anionized and cationized hemeundecapeptides as probes for cell surface charge and permeability studies: Differentiated labeling of endothelial plasmalemmal vesicles, J. Cell Biol., 100, 606-612, 1985.
6. Simionescu, M., Simionescu, N., and Palade, G. E., Differentiated microdomains on the luminal surface of the capillary endothelium. I. partial characterization of their anionic sites, J. Cell Biol., 90, 614-621, 1981.
7. Movat, H. Z., The role of histamine and other mediators in microvascular changes in acute inflammation, Can. J. Physiol. Pharmacol., 65, 451-157, 1987.
8. Mylecharane, E. J., Mechanisms involved in serotonin-induced vasodilation, Blood Vessels, 27, 116-126, 1990.
9. Vercellotti, G. M. and Tolins, J. P., Endothelial activation and the kidney: Vasomediator modulation and antioxidant strategies, Am. J. Kidney Dis., 21, 331-343, 1993.
10. van Hinsbergh, V. W., The endothelium: Vascular control of haemostasis, Atherosclerosis, 95, 198-201, 2001.
11. Hobbs, S. K. et al., Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment, Proc. Natl Acad. Sci. USA, 95, 4607-4612, 1998.
12. Yuan, F. et al., Vascular permeability in ahuman tumor xenograft: Molecular size dependence and cutoffsize, Cancer Res., 55, 3752-3756, 1995.
13. Hudson, B. G., Reeders, S. T., and Trygvason, K., Type IV collagen: Structure, gene organization and role in human diseases, J. Biol. Chem., 268, 26033-26036, 1993.
14. Gorog, P. and Pearson, J. D., Sialic acid moieties on surface glycoproteins protect endothelial cells from proteolytic damage, J. Pathol., 146, 205-212, 1985.
15. Hallmann, R. et al., Expression of function of laminins in the embryonic and mature vasculature, Physiol. Rev., 85, 979-1000, 2005.
16. Sund, M., Xie, L., and Kalluri, R., The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis, APMIS, 112, 450-462, 2004.
17. Ruoslahti, E., Structure and biology of proteoglycans, Annu. Rev. Cell Biol., 4, 229-255, 1988.
18. Ruoslahti, E., Specialization of tumor vasculature, Nat. Rev. Cancer, 2, 83-90, 2002.
19. Satoh, A., Toida, T., Yoshida, K., Kojima, K., and Matsumoto, I., New role of glycosaminoglycans on the plasma membrane proposed by their interaction with phosphatidylcholine, FEBS Lett., 477, 249-252, 2000.
20. Folkman, J. and Haudenschild, C., Angiogenesis by capillary endothelial cells in culture, Trans. Ophthalmol. Soc. UK, 100, 346-353, 1980.
21. Michiels, C., Arnould, T., and Remacle, J., Endothelial cell responses to hypoxia: Initiation of a cascade of cellular interactions, Biochim. Biophys. Acta, 1497, 1-10, 2000.
22. Charonis, A. S. and Wissig, S. L., Anionic sites in basement membranes. Differences in their electrostatic properties in continuous and fenestrated capillaries, Microvasc. Res., 25, 265-285, 1983.
23. Roberts, W. G. and Palade, G. E., Neovasculature induced by vascular endothelial growth factor is fenestrated, Cancer Res., 57, 765-772, 1997.
24. Ran, S., Downes, A., and Thorpe, P. E., Increased exposure of anionic phospholipids on the surface of tumor blood vessels, Cancer Res., 62, 6132-6140, 2002.
25. Vincent, S., DePace, D., and Finkelstein, S., Distribution of anionic sites on the capillary endothelium in an experimental brain tumor model, Microcirc. Endothleium Lymphatics, 45-67, 1988.
26. Vijayagopal, P., Figueoroa, J. E., and Levine, E. A., Altered composition and increased endothelial cell proliferative activity of proteoglycans isolated from breast carcinoma, J. Surg. Oncol., 68, 250-254, 1998.
27. Denekamp, J. and Hobson, B., Endothelial-cell proliferation in experimental tumours, Br. J. Cancer, 46, 711-720, 1982.
28. Denekamp, J., Vasculature as atarget for tumor therapy, Prog. Appl. Microcirc., 4, 28-38, 1984.
29. Jain, R. K., The next frontier of molecular medicine: Delivery of therapeutics, Nat. Med., 4, 655-657, 1998.
30. Folkman, J., Tumor angiogenesis: Therapeutic implications, N. Engl. J. Med., 285, 1182-1186, 1971.
31. Campbell, R. B. et al., Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors, Cancer Res., 62, 6831-6836, 2002.
32. Chang, Y. S. et al., Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood, Proc. Natl Acad. Sci. USA, 97, 14608-14613, 2000.
33. Arap, W., Pasqualini, R., and Ruoslahti, E., Cancer treatment by targeted drug delivery to tumor vasculature in amouse model, Science, 279, 377-380, 1998.
34. Bloemen, P. G. et al., Adhesion molecules: Anew target for immunoliposome-mediated drug delivery, FEBS Lett., 357, 140-144, 1995.
35. Spragg, D. D. et al., Immunotargeting of liposomes to activated vascular endothelial cells: Astrategy for site-specific delivery in the cardiovascular system, Proc. Natl Acad. Sci. USA, 94, 8795-8800, 1997.
36. Thorpe, P. E. and Burrows, F. J., Antibody-directed targeting of the vasculature of solid tumors, Breast Cancer Res. Treat., 36, 237-251, 1995.
37. Rettig, W. J. et al., Identification of endosialin, acancer surface glycoprotein of vascular endothelial cells in human cancer, Proc. Natl Acad. Sci. USA, 89, 10832-10836, 1992.
38. Thurston, G. et al., Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice, J. Clin. lnvestig., 101, 1401-1413, 1998.
39. Mislick, K. A. and Baldeschwieler, J. D., Evidence for the role of proteoglycans in cation-mediated gene transfer, Proc. Natl Acad. Sci. USA, 93, 12349-12354, 1996.
40. Hardebo, J. E. and Kahrstrom, J., Endothelial negative surface charge areas and blood-brain barrier function, Acta Physiol. Scand., 125, 495-199, 1985.
41. Nag, S., Role of the endothelial cytoskeleton in blood-brain-barrier permeability to proteins, Acta Neuropathol. (Berl.), 90, 454-460, 1995.
42. Nag, S., Blood-brain barrier permeability using tracers and immunohistochemistry, Methods Mol. Med., 89, 133-144, 2003.
43. Renkin, E. M., Transport of macromolecules: Pores and other endothelial pathways, Appl. Physiol., 58, 315-325, 1985.
44. Renkin, E. M., Multiple pathways of capillary permeability, Circ. Res., 41, 735-743, 1977.
45. Gabizon, A. A., Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet, Clin. Cancer Res., 7, 223-225, 2001.
46. Yuan, F. et al., Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in ahuman tumor xenograft, Cancer Res., 54, 3352-3356, 1994.
47. Papahadjopoulos, D. et al., Sterically stabilized liposomes: Improvements in pharmacokinetics and anti-tumor efficacy, Proc. Natl Acad. Sci. USA, 88, 11460-11464, 1991.
48. Campbell, R. B., Balasubramanian, S. V., and Straubinger, R. M., Physical properties of phospho-lipid-cationic lipid interactions: Influences on domain structure, liposome size and cellular uptake, Biochim. Biophys. Acta, 1512, 27-39, 2001.
49. Campbell, R. B., Balasubramanian, S. V., and Straubinger, R. M., Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes, J. Pharm. Sci., 90, 1091-1105, 2001.
50. Torchilin, V. P., Polymer-coatedlongcirculating microparticulatepharmaceuticals, J. Microencapsul., 15, 1-19, 1998.
51. Szoka, F and Papahadjopoulos, D, Comparative properties and methods of preparation of lipid vesicles (liposomes), Annu. Rev. Biophys. Bioeng., 9, 467-508, 1980.
52. Levchenko, T S, Rammohan, R, Lukyanov, A N, Whiteman, K R, and Torchilin, V P, Liposome clearance in mice: The effect of aseparate and combined presence of surface charge and polymer coating, Int. J. Pharm., 240, 95-102, 2002.
53. Straubinger, R. M., pH-Sensitive liposomes for delivery of macromolecules into cytoplasm of cultured cells, Methods Enzymol., 221, 361-376, 1993.
54. Simberg, G., Weisman, S., Talmon, Y., and Barenholz, Y., DOTAP (and other cationic lipids): Chemistry, biophysics, and transfection, Crit. Rev. Ther. Drug Carrier Syst., 21, 257-317, 2004.
55. Jain, R. K., Munn, L. L., and Fukumura, D., Dissecting tumour pathophysiology using intravital microscopy, Nat. Rev. Cancer, 2, 266-276, 2002.
56. Hashizume, H. et al., Openings between defective endothelial cells explain tumor vessel leakiness, Am. J. Pathol., 156, 1363-1380, 2000.
57. Fukumura, D., Yuan, F., Monsky, W. L., Chen, Y., and Jain, R. K., Effect of host microenvironment on the microcirculation of human adenocarcinoma, Am. J. Pathol., 151, 679-688, 1997.
58. Felgne, P. et al., Lipofection: Ahighly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl Acad. Sci. USA, 84, 7413-7417, 1987.
59. Felgner, P. L. and Ringold, G. M., Cationic liposome-mediated transfection, Nature, 337, 387-388, 1989.
60. Sakurai, F. et al., Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression, J. Control. Release, 255-269, 2000.
61. Dabbas, S., Kaushik, R., Dandamudi, S., and Campbell, R.B., Physiochemical evaluation of PEG-modified cationic liposomes (PCLs) and properties in vitro using human primary and immortalized microvascular endothelial cells. J. Pharm. Sci. Submitted.
62. Dellian, M., Yuan, F., Trubetskoy, V. S., Torchilin, V. P., and Jain, R. K., Vascular permeability in a human tumor xenograft: Molecular charge dependence, Br. J. Cancer, 82, 1513-1518, 2000.
63. McLean, J. W. et al., Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice, Am. J. Physiol., 273, 387-404, 1997.
64. Tanner, F., Carr, D. P., Nabel, G. J., and Nabel, E. G., Transfection of human endothelial cells, Cardiovasc. Res., 35, 522-528, 1997.
65. Matsumura, J. S., Kim, R., Shively, V. P., MacDonald, R. C., and Pearce, W. H., Characterization of vascular gene transfer using anovel cationic lipid, J. Surg. Res., 85, 339-345, 1999.
66. Nabel, G. J. et al., Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans, Proc. Natl Acad. Sci. USA, 90, 11307-11311, 1993.
67. Pleyer, U. et al., Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells, Exp. Eye Res., 73, 1-7, 2001.
68. Uyechi, L. S., Gagne, L., Thurston, G., and Szoka, F. C. J., Mechanism of lipoplex gene delivery in mouse lung: Binding and internalization of fluorescent lipid and DNA components, Gene Ther., 8, 828-836, 2001.
69. Trubetskoy V. S. Torchilin V. P. Kennel S. and Huang L. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly(L-lysine)-antibody conjugate in mouse lung endothelial cells, Biochim. Biophys. Acta, 1131, 311-313, 1992.
70. Abraham, N. G. et al., Transfection of the human heme oxygenase gene into rabbit coronary micro-vessel endothelial cells: Protective effect against heme hemoglobin toxicity, Proc. Natl Acad. Sci. USA, 92, 6798-6802, 1995.
71. Nakatani, K. et al., Endothelial adhesion molecules in glomerular lesions: Association with their severity and diversity in lupus models, Kidney Int., 65, 1290-1300, 2004.
72. Jeschke, M. G. et al., IGF-I gene transfer in thermally injured rats, Gene Ther., 6, 1015-1020, 1999.
73. Pickering, J. G. et al., Liposome-mediated gene transfer into human vascular smooth muscle cells, Circulation, 89, 13-21, 1994.
74. Tiukinhoy, S. D. et al., Development of echogenic, plasmid-incorporated, tissue-targeted cationic liposomes that can be used for directed gene delivery, Invest. Radiol., 35, 732-738, 2000.
75. Hong, Z. et al., Enhanced adeno-associated virus vector expression by adenovirus protein-cationic liposome complex, Chin. Med. J., 108, 332-337, 1995.
76. Torchilin, V. P., Liposomes as targetable drug carriers, CRC Crit. Rev. Ther. Drug Carrier Syst., 2, 65-115, 1985.
77. Ishida, T., Harashima, H., and Kiwada, H., Liposome clearance, Biosci. Reports, 22, 197-224, 2002.
78. Harrington, K. J., Lewanski, C. R., and Stewart, J. S., Liposomes as vehicles for targeted therapy of cancer. Part 2. Clinical development, Clin. Oncol., 12, 16-24, 2000.
79. Gabizon, A. and Paphadjopoulos, D., Liposome formulations with prolonged circulation time in blood and enhanced uptake in tumours, Proc. Natl Acad. Sci., 85, 6949-6953, 1985.
80. Woodle, M. C. and Lasic, D. L., Sterically stabilized liposomes, Biochim. Biophys. Acta, 1113, 171-199, 1992.
81. Meyer, O. et al., Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides, J. Biol. Chem., 273, 15621-15627, 1998.
82. Gursel, I., Gursel, M., Ishii, K. J., and Klinman, D. M., Sterically stabilized cationic liposomes improved the uptake and immunostimulatory activity of CpG oligonucleotides, J. lmmunol., 167, 3324-3328, 2001.
83. Harigai, T. et al., Preferential binding of polyethylene glycol-coated liposomes containing anovel cationic lipid, TRX-20, to human subendothelial cells via chondroitin sulfate, Pharm. Res., 18, 1284-1290, 2001.
84. Strawn, L. M. and Shawver, L. K., Tyrosine kinase in disease: Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials, Expert Opin. Investig. Drugs, 7, 553-573, 1998.
85. Mendel, D. B. et al., The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function, Clin. Cancer Res., 6, 4848-4858, 2000.
86. Brower, V., Tumor angiogenesis-new drugs on the block, Nat. Biotechnol., 17, 963-968, 1999.
87. Hirabayashi, K., Yano, J., Takesue, H., Fujiwara, N., and Irimura, T., Inhibition of metastatic carcinoma cell growth in livers by poly(I):poly(C)/cationic liposome complex (LIC), Oncol. Res., 11, 497-504, 1999.
88. Lee, C. M. et al., Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo, Cancer Res., 62, 4282-4288, 2002.
89. Hood, J. D. and Cheresh, D. A., Role of integrins in cell invasion and migration, Nat. Rev. Cancer, 2, 91-100, 2002.
90. Akalu, A., Cretu, A., and Brooks, P. C., Targeting integrins for control of tumour angiogenesis, Expert Opin. lnvestig. Drugs, 14, 1475-1486, 2005.
91. Hood, J. D. et al., Tumor regression by targeted gene delivery to the neovasculature, Science, 296, 2404-2407, 2002.
92. Shinkarauk, S., Bayle, M., Lain, G., and Deleris, G., Vascular endothelial cell growth factor (VEGF), an emerging target for cancer therapy, Curr. Med. Chem. Anti-Cancer. Agents, 3, 95-117, 2003.
93. Senger, D. R. et al., Vascular permeability factor (VPF, VEGF) in tumor biology, Metastasis Rev., 12, 303-324, 1993.
94. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M., Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis, Am. J. Pathol., 146, 1029-1039, 1995.